Inflammation, endothelial dysfunction, and the risk of high blood pressure: epidemiologic and biological evidence
Tóm tắt
Từ khóa
Tài liệu tham khảo
Burt VL et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension 1995; 25: 305–313.
Hodgson TA, Cai L . Medical care expenditures for hypertension, its complications, and its comorbidities. Med Care 2001; 39: 599–615.
Ridker PM et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767–1772.
Ridker PM et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836–843.
Ridker PM et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973–979.
Sinisalo J et al. Relation of inflammation to vascular function in patients with coronary heart disease. Atherosclerosis 2000; 149: 403–411.
Hingorani AD et al. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation 2000; 102: 994–999.
Panza JA et al. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323: 22–27.
Iiyama K et al. Impaired endothelial function with essential hypertension assessed by ultrasonography. Am Heart J 1996; 132: 779–782.
Zizek B et al. Endothelial dysfunction in hypertensive patients and in normotensive offspring of subjects with essential hypertension. Heart 2001; 85: 215–217.
Taddei S et al. Endothelium-dependent forearm vasodilation is reduced in normotensive subjects with familial history of hypertension. J Cardiovasc Pharmacol 1992; 20 (Suppl 12): S193–S195.
Mendall MA et al. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 1996; 312: 1061–1065.
Tracy RP et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vase Biol 1997; 17: 2167–2176.
Hak AE et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vase Biol 1999; 19: 1986–1991.
Koenig W et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237–242.
Yudkin JS et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19: 972–978.
Ford ES, Giles WH . Serum C-reactive protein and self-reported stroke: findings from the Third National Health and Nutrition Examination Survey. Arterioscler Thromb Vase Biol 2000; 20: 1052–1056.
Doggen CJ et al. C-reactive protein, cardiovascular risk factors and the association with myocardial infarction in men. J Intern Med 2000; 248: 406–414.
Margaglione M et al. C-reactive protein in offspring is associated with the occurrence of myocardial infarction in first-degree relatives. Arterioscler Thromb Vase Biol 2000; 20: 198–203.
Festa A et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42–47.
Onat A et al. C-reactive protein and coronary heart disease in western Turkey. Am J Cardiol 2001; 88: 601–607.
Yamada S et al. Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population: Jichi Medical School Cohort Study. Am J Epidemiol 2001; 153: 1183–1190.
Bautista LE et al. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens 2001; 19: 857–861.
Rohde LE et al. Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. Am J Cardiol 1999; 84: 1018–1022.
Bellelli G et al. Lack of nighttime dipping of blood pressure in hypertensive elderly patients is associated with elevated C-reactive protein serum levels. J Hypertens 2001; 191: 2107.
Mendall MA et al. Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart 1997; 78: 273–277.
Rifai N et al. Inflammatory markers in men with angiographically documented coronary heart disease. Clin Chem 1999; 45: 1967–1973.
Sheu WHH et al. Plasma tumor necrosis factor alpha levels and insulin sensitivity in hypertensive subjects. Clin Exp Hypertens 2000; 22: 595–606.
Volpato S et al. Cardiovascular disease, interleukin-6, and risk of mortality in older women: the women's health and aging study. Circulation 2001; 103: 947–953.
Fernandez-Real JM et al. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 2001; 86: 1154–1159.
Chae CU et al. Blood pressure and inflammation in apparently healthy men. Hypertension 2001; 38: 399–403.
Ito H et al. Association of serum tumor necrosis factor-alpha with serum low-density lipoprotein-cholesterol and blood pressure in apparently healthy Japanese women. Clin Exp Pharmacol Physiol 2001; 28: 188–192.
Furumoto T et al. Association of cardiovascular risk factors and endothelial dysfunction in Japanese hypertensive patients: implications for early atherosclerosis. Hypertens Res 2002; 25: 475–480.
Woods A et al. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J 2000; 21: 1574–1583.
Tilg H et al. IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today 1997; 18: 428–432.
Bhagat K, Vallance P . Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation 1997; 96: 3042–3047.
Dorffel Y et al. Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension 1999; 34: 113–117.
Zinman B et al. Circulating tumor necrosis factor-alpha concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J Clin Endocrinol Metab 1999; 84: 272–278.
Hotamisligil GS et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409–2415.
Pausova Z et al. Role of tumor necrosis factor-alpha gene locus in obesity and obesity-associated hypertension in French Canadians. Hypertension 2000; 36: 14–19.
Dalziel B et al. Association of the TNF-alpha-308 G/A promoter polymorphism with insulin resistance in obesity. Obes Res 2002; 10: 401–407.
Ferreri NR et al. Tumor necrosis factor-alpha-angiotensin interactions and regulation of blood pressure. J Hypertens 1997; 15: 1481–1484.
Reid IA . Vasoactive Peptides. In: BG Katzung (ed). Basic and Clinical Pharmacology. Lange Medical Books/McGraw-Hill: New York, NY, 2001, pp 292–310.
Fernandez-Real JM et al. Shedding of TNF-alpha receptors, blood pressure, and insulin sensitivity in type 2 diabetes mellitus. Am J Physiol Endocrinol Metab 2002; 282: 952–959.
Accini JL et al. Colombian Study to Assess the Use of Noninvasive Determination of Endothelium-Mediated Vasodilation (CANDEV). Normal values and factors associated. Endothelium 2001; 86: 157–166.
Cao H, Hegele RA . Human C-reactive protein (CRP) 1059G/C polymorphism. Hypertension 2000; 45: 100–101.
Pankow JS et al. Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study. Atherosclerosis 2001; 154: 681–689.
Palmer RM et al. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524–526.
Taylor SG, Weston AH . Endothelium-derived hyperpolarizing factor: a new endogenous inhibitor from the vascular endothelium. Trends Pharmacol Sci 1988; 9: 272–274.
Bunting S et al. Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation. Prostaglandins 1976; 12: 897–913.
Palmer RM et al. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333: 664–666.
Vane JR, Botting RM . Formation by the endothelium of prostacyclin, nitric oxide and endothelin. J Lipid Mediat 1993; 6: 395–404.
Moncada S, Higgs EA . Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J 1995; 9: 1319–1330.
Garland CJ et al. Endothelium-dependent hyperpolarization: a role in the control of vascular tone. Trends Pharmacol Sci 1995; 16: 23–30.
Moncada S, Vane JR . Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev 1978; 30: 293–331.
Pomerantz KB, Hajjar DP . Eicosanoids in regulation of arterial smooth muscle cell phenotype, proliferative capacity, and cholesterol metabolism. Arteriosclerosis 1989; 9: 413–429.
Diederich D et al. Impaired endothelium-dependent relaxations in hypertensive resistance arteries involve cyclooxygenase pathway. Am J Physiol 1990; 258: H445–H451.
Luscher TF, Barton M . Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000; 102: 2434–2440.
Boulanger CM . Secondary endothelial dysfunction: hypertension and heart failure. J Mol Cell Cardiol 1999; 31: 39–49.
Hirata Y et al. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 1993; 91: 1367–1373.
Hamberg M et al. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72: 2994–2998.
Bouloumie A et al. Endothelial dysfunction coincides with an enhanced nitric oxide synthase expression and superoxide anion production. Hypertension 1997; 30: 934–941.
Gryglewski RJ et al. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986; 320: 454–456.
Morrow JD et al. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990; 87: 9383–9387.
Delanty N et al. 8-Epi PGF2 alpha generation during coronary reperfusion. A potential quantitative marker of oxidant stress in vivo. Circulation 1997; 95: 2492–2499.
Vallance P et al. Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? Lancet 1997; 349: 1391–1392.
Bhagat K et al. Endothelial ‘stunning’ following a brief exposure to endotoxin: a mechanism to link infection and infarction? Cardiovasc Res 1996; 32: 822–829.
Taddei S et al. Cyclooxygenase inhibition restores nitric oxide activity in essential hypertension. Hypertension 1997; 29: 274–279.
Taddei S et al. Defective L-arginine-nitric oxide pathway in offspring of essential hypertensive patients. Circulation 1996; 94: 1298–1303.
Tesfamariam B, Ogletree ML . Dissociation of endothelial cell dysfunction and blood pressure in SHR. Am J Physiol 1995; 269: H189–H194.
Ritter JM et al. Thromboxane A2 receptor antagonism and synthase inhibition in essential hypertension. Hypertension 1993; 22: 197–203.
Taddei S et al. Hypertension causes premature aging of endothelial function in humans. Hypertension 1997; 29: 736–743.
Yoshizumi M et al. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 1993; 73: 205–209.
Verma S et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002; 106: 913–919.
Heitzer T et al. Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia. Role of oxidized LDL. Circulation 1996; 93: 1346–1353.
Pleiner J et al. High doses of vitamin C reverse Escherichia coli endotoxin-induced hyporeactivity to acetylcholine in the human forearm. Circulation 2002; 106: 1460–1464.
Taddei S et al. Effects of antihypertensive drugs on endothelial dysfunction: clinical implications. Drugs 2002; 62: 265–284.
Perticone F et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104: 191–196.
Nomura S et al. High-shear-stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. Atherosclerosis 2001; 158: 277–287.
Sterpetti AV et al. Shear stress increases the release of interleukin-1 and interleukin-6 by aortic endothelial cells. Surgery 1993; 114: 911–914.
Chobanian AV, Alexander RW . Exacerbation of atherosclerosis by hypertension. Potential mechanisms and clinical implications. Arch Intern Med 1996; 156: 1952–1956.
Tracy RP et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vase Biol 1997; 17: 1121–1127.
Panza JA . Endothelium, nitric oxide, and hypertension. In Panza JA, Cannon RO III (eds): Endothelium, Nitric Oxide, and Atherosclerosis. Futura Publishing Co, Inc., Armonk, NY, 1999; pp 147–162.
Panza JA et al. Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. J Am Coll Cardiol 1993; 21: 1145–1151.
Anderson TJ et al. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol 2000; 35: 60–66.